Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could bring relief to teens with severe eczema

NCT ID NCT07309055

Recruiting now Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 20, 2026 · Updated 26 times

Summary

This study tests an injection called SHR-1819 in 201 teens aged 12 to 17 with severe atopic dermatitis (eczema). The goal is to see if it safely reduces skin redness, itching, and rash better than a placebo. Participants receive the drug or placebo for several weeks, and doctors measure improvements using standard eczema scores.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110002, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200092, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS